IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical reported a 70% increase in its U.S. active commercial install base for the ProSense system following FDA marketing authorization received in October 2025. The growth is driven by updated clinical guidelines from the American Society of Breast Surgeons and rising patient awareness, supported by media coverage across approximately 190 local TV stations.
Key figures
- Media coverage station count
- 190
- Us install base growth percent
- 70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.